Identity
Cortagen is a synthetic tetrapeptide with the sequence alanine–glutamic acid–aspartic acid–proline (Ala-Glu-Asp-Pro, abbreviated AEDP). It was produced by directed synthesis following amino acid analysis of Cortexin, a polypeptide preparation extracted from the cerebral cortex of cattle or pigs.
That derivation is the single most important thing to understand about it. Cortexin is a mixture of dozens of peptides in varying ratios, and it has been a registered medicine in Russia and other former Soviet states for decades, used mainly in ischaemic stroke rehabilitation and neurological practice. Cortagen is one defined four-residue peptide chosen from the analysis of that mixture. The relationship is structurally identical to epithalamin (extract) and epitalon (synthetic peptide) in the same programme — and it produces the same recurring confusion, in which clinical familiarity earned by the extract is transferred to the synthetic compound.
Within the bioregulator family, Cortagen is the cortex-addressed member, alongside Pinealon (EDR, brain), Epitalon (AEDG, pineal), Cardiogen (heart), Bronchogen (lung), Cartalax (cartilage) and others.
Development & history
- 1980s onward: Khavinson's group at the St Petersburg Institute of Bioregulation and Gerontology develops the bioregulator programme, moving from tissue extracts (cytomedins) to defined synthetic short peptides (cytogens). Cortexin represents the extract stage for cortical tissue; Cortagen the synthetic stage.
- 2002: Kazakova and colleagues report in vitro effects of short peptides, including Cortagen, on interleukin-2 gene expression in splenocytes (Bull Exp Biol Med).
- 2004: Anisimov, Khavinson and Anisimov publish the most-cited mechanistic study — a microarray analysis of Cortagen's effect on gene expression in mouse heart (Neuroendocrinology Letters). The choice of tissue is notable for a compound positioned as cortex-specific.
- 2007: The same lineage publishes methodological work on applying DNA microarray technology to gerontological studies (Methods Mol Biol).
- 2015: Lezhava and colleagues — a Georgian group, working within the bioregulator framework but outside Khavinson's institute — report epigenetic regulation of "aged" heterochromatin by Cortagen (Int J Pept Res Ther). This is the closest thing to independent work identified for the compound.
- Preclinical strand: rodent studies reported by the originating programme describe improved sciatic nerve regeneration, cortical explant tissue growth, improved spatial learning, increased hippocampal BDNF and protection against oxidative neuronal injury.
- To date: no human clinical trial of Cortagen has been published or registered.
Mechanism (as proposed)
The proposed mechanism is the class mechanism. Peptides of two to four residues are held to be small enough to cross the plasma membrane and nuclear envelope without receptor mediation, then to bind DNA and histone proteins directly, modulating chromatin structure and the transcription of tissue-specific genes. Each bioregulator is assigned an organ address — Cortagen to the cerebral cortex — with specificity attributed to cognate motifs in tissue-specific promoter regions. Downstream, this is proposed to restore neurotrophic factor expression (BDNF, NGF), reduce neuroinflammatory signalling and support neuronal survival.
Two honest observations about this. First, the supporting gene expression data are real measurements, but they are not what the claim requires: showing that Cortagen alters transcription in mouse heart or IL-2 expression in splenocytes demonstrates some transcriptional effect somewhere, not cortex-specific genomic targeting. Second, the framework's architecture — one short peptide per organ, each with its own genomic address — is unusually tidy for biology, and it happens to be a structure that can generate an indefinite number of marketable compounds. That is not a refutation, but it warrants scepticism proportionate to the claim.
Reading the evidence honestly
Three points, in descending order of importance.
The human evidence belongs to a different substance. Cortexin — the crude extract — has decades of clinical use in Russian neurology and a body of associated clinical literature. Cortagen — the synthetic tetrapeptide — has none. When a source says "Russian clinical literature reports benefit," it is almost always describing the extract. This distinction gets lost constantly, and it matters: a defined single peptide is not a stand-in for a mixture of dozens, and the programme's own history shows the two can diverge (as epitalon and epithalamin did on melatonin).
There is essentially no independent work. One Georgian group's 2015 heterochromatin paper is the nearest thing found. Otherwise the literature traces to the originating institute, and the bulk of what is written about Cortagen comes from vendors rather than scientists. When suppliers are the main information source, ordinary scientific correction does not operate.
The dosing figures circulating online are inventions. Commonly cited protocols — 200-400 mcg subcutaneously for 10-20 days, or 10-20 mg orally daily — are community conventions built by analogy to how bioregulators were administered in preclinical work. They are not derived from any human trial, because none exists. Some vendor sources state this outright, which is to their credit and worth repeating here.
The grade reflects a defined, chemically real peptide with a coherent theoretical framework, modest and largely single-source preclinical data, an extraordinary unconfirmed mechanistic claim, and no human evidence of its own — sold on clinical credibility that belongs to a different preparation.